Hill-Rom (NYSE:HRC) posted its quarterly earnings data on Friday. The medical technology company reported $1.95 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.46 by $0.49, MarketWatch Earnings reports. Hill-Rom had a net margin of 5.04% and a return on equity of 22.60%. The company had revenue of $767.50 million during the quarter, compared to analysts’ expectations of $749.39 million. During the same period in the prior year, the business posted $1.23 earnings per share. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. Hill-Rom updated its FY 2020
Pre-Market guidance to 5.40 EPS.
HRC stock opened at $97.22 on Friday. The company has a current ratio of 1.52, a quick ratio of 1.22 and a debt-to-equity ratio of 1.20. The firm has a market cap of $6.47 billion, a P/E ratio of 44.60, a P/E/G ratio of 1.14 and a beta of 0.72. Hill-Rom has a 12-month low of $72.29 and a 12-month high of $117.68. The stock’s 50 day simple moving average is $107.95 and its 200 day simple moving average is $105.06.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Friday, September 18th will be given a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date of this dividend is Thursday, September 17th. Hill-Rom’s payout ratio is 17.32%.
A number of research firms have commented on HRC. UBS Group decreased their target price on shares of Hill-Rom from $130.00 to $125.00 and set a “buy” rating on the stock in a research report on Monday, May 4th. Needham & Company LLC dropped their price target on shares of Hill-Rom from $131.00 to $129.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Barclays reiterated a “buy” rating and issued a $125.00 price objective on shares of Hill-Rom in a research report on Tuesday, April 14th. Five research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $125.80.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Featured Article: What is the S&P/ASX 200 Index?
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.